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Introduction: Treatment of locally advanced non–small cell
lung cancer with chemoradiotherapy (CRT) is limited by
development of toxicity in normal tissue, including radia-
tion esophagitis (RE). Increasingly, 18F-ﬂuorodeoxyglucose
(FDG) positron emission tomography (PET) is being used
for adaptive planning. Our aim was to assess changes in
esophageal FDG uptake during CRT and relate the changes
to the onset and severity of RE.
Methods: This prospective study in patients with stage II–
III non–small cell lung cancer involved serial four-
dimensional computed tomography and PET scans during
CRT (60–74Gy). RE was recorded weekly using the Com-
mon Terminology Criteria for Adverse Events (v4.0), and
imaging was performed at weeks 0, 2, 4, and 7. Changes in
the esophagus’s peak standard uptake value (SUVpeak) were
analyzed for each time point and correlated with grade of
RE using the Wilcoxon rank-sum test. The volume of
esophagus receiving 50 Gy (V50) and volume of esophagus
receiving 60 Gy (V60) were correlated with the develop-
ment of RE, and the C-statistic (area under the curve [AUC])
was calculated to measure predictivity of grade 3 RE.
Results: RE developed in 20 of 27 patients (74%), with
grade 3 reached in 6 (22%). A signiﬁcant percentage in-
crease in SUVpeak in the patients with RE was noted at week
4 (p ¼ 0.01) and week 7 (p ¼ 0.03). For grade 3 RE, a
signiﬁcant percentage increase in SUVpeak was noted at
week 2 (p ¼ 0.01) and week 7 (p ¼ 0.03) compared with
that for less than grade 3 RE. Median V50 (46.3%) and V60
(33.4%) were signiﬁcantly higher in patients with RE
(p ¼ 0.04). The AUC measurements suggested that thepercentage change in SUVpeak at week 2 (AUC ¼ 0.69) and
V50 (AUC ¼ 0.67) and V60 (AUC ¼ 0.66) were similarly
predictive of grade 3 RE.
Conclusions: Serial FDG-PET images during CRT show
signiﬁcant increases in SUVpeak for patients in whom RE
develops. The changes at week 2 may predict those at risk
for the development of grade 3 RE and may be informative
for adaptive planning and early intervention.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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Dose escalation and adaptive radiation therapy have
been proposed for use in managing locally advanced
non–small cell lung cancer (NSCLC). Unfortunately, suchJournal of Thoracic Oncology Vol. 11 No. 2: 213-221
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toxicity in normal tissue, particularly radiation esopha-
gitis (RE).1,2 Still, the current standard chemoradio-
therapy (CRT) regimens yield poor outcomes, with the
5-year overall survival rate at 15%.1
Grade 3 RE will develop in approximately 18% of
patients undergoing CRT1,3; it is associated with severe
morbidity and can necessitate supportive feeding and
hospital admissions and can also potentially prolong
treatment times and negatively affect overall survival.4
Several dosimetric and volumetric factors have been
suggested to be predictive of RE, including mean
esophageal dose,5 esophagus length, and volume of
esophagus receiving greater than 50 Gy (V50)6 or 60 Gy
(V60), as is shown in the meta-analysis by Palma et al.3
18F-ﬂuorodeoxyglucose–positron emission tomogra-
phy (FDG-PET) imaging is established in staging lung
cancers and has been shown to correlate with outcomes
after CRT.4,7–9 Using FDG-PET to plan radiotherapy
improves accuracy of contouring10,11 and can aid in
adaptive planning to boost regions of high or residual
uptake.12–14 The optimal timing of dose escalation is to
be determined12,13; however, meeting normal tissue
constraints to avoid damage remains a limiting factor.
There are few studies reporting FDG-PET changes in
relation to development of RE. Nijkamp et al. showed
PET changes within 3 months after CRT in patients in
whom RE developed,15 whereas Yuan et al. showed that
PET standard uptake value (SUV) increased signiﬁcantly
after 45 Gy of radiotherapy, particularly in patients with
stage III lung cancer who were receiving concurrent
chemotherapy, and they hypothesized that this increase
could be predictive of RE.7
The primary objective of this study was to assess FDG
avidity within the esophagus at set intervals during a
course of CRT and relate the observed changes in uptake
to onset of any grade of RE and onset of grade 3 toxicity.
The secondary objective was to relate physical dose
parameters to the observed FDG-PET changes and assess
which would be most predictive of grade 3 toxicity.
Methods
This was a prospective single-institution, single-arm
cohort study of FDG-PET imaging during CRT for
patients with locally advanced NSCLC. The patients
enrolled had inoperable histologically conﬁrmed NSCLC
but were deemed suitable for concurrent platinum-
based chemotherapy with radical radiotherapy.
Patients received 60 Gy to 74 Gy (2 Gy per fraction). All
study patients underwent four-dimensional (4D) FDG-
PET/computed tomography (CT) scans for radio-
therapy planning at week 0; for response monitoring at
weeks 2, 4, and 7 during CRT; and subsequently at a
3-month follow-up. Patients were evaluated weeklyduring treatment, and RE was recorded using the Com-
mon Terminology Criteria for Adverse Events (v4.0).
All 4D PET/CT scans were performed in the treat-
ment position on a dedicated PET-CT simulator (Dis-
covery ST, GE Healthcare, Milwaukee, WI). Patients were
fasted and had regular blood glucose monitoring before
receiving the injection of FDG (5 MBq/kg) for the PET
scan. All PET/CT scans for the given week were inher-
ently coregistered, and both exhale and inhale scans
were transferred into our clinical treatment planning
system (Pinnacle3, version 9.0, Philips Radiation
Oncology Systems, Milpitas, CA) for contouring, image
registration, and plan generation. The 4D images from
subsequent weeks were coregistered to the planning
scans on the basis of the exhale 4D CT scans and a rigid
registration based on bony anatomy and the carina.
Quality of the registration was assessed by a physicist
and a physician before contouring.
The gross tumor volume (GTV) was contoured on the
planning 4D CT data set, copied onto the data sets con-
taining registered PET-CT data, and modiﬁed according
to FDG uptake. Clinical target volume expansions of
5 mm were created on both inhale and exhale images
and combined to form the internal target volume (ITV),
and an additional 5 mm expansion was added to ITV to
form the planning target volume.16 Organs at risk were
contoured on the exhale 4D CT data set according to our
standard protocol for planning lung treatment.
The esophagus was contoured from cricoid to
gastroesophageal junction on the basis of CT images and
then transferred to the coregistered PET data set.
Figure 1 illustrates an example case of a coregistered
PET with dosimetric information showing the change in
PET uptake seen in GTV on week 2 and the changes
within the esophagus by week 7. Previous studies sug-
gested FDG-PET changes from RE are seen mainly at the
level of the tumor,7 which correlates with the areas
receiving higher radiation doses. To evaluate the FDG-
PET changes caused by RE, we segmented the esoph-
agus into two regions, one receiving more than 5 Gy
(ESO-A) and the other serving as a background region
receiving less than 5 Gy (ESO-B). This segmentation
allowed us to use the esophagus as its own control and
compare changes in FDG-PET uptake that were due to
radiation delivery.
Many patients had tumor or nodal disease adjacent to
the esophagus, for which FDG-PET uptake was expected
to decrease with treatment. We therefore analyzed
ESO-A after excluding the region within 5 mm of the ITV
to reduce confounding FDG-PET changes related to
tumor response, as shown in Figure 2.
Peak SUV (SUVpeak), deﬁned by the 95th percentile,
was used for evaluation because it was considered more
reproducible and less inﬂuenced by outlying values than
Figure 1. Computed tomography with dose distribution (green, red, and yellow isodose curves) and corresponding positron
emission tomography images demonstrating changes within the esophagus (contour) from week 2 to week 7 of
chemoradiation.
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17 The SUVpeak for each region was determined
on the exhale 4D PET scan. We evaluated the percentage
increase in SUVpeak in ESO-A compared with that in the
background (ESO-B) by using the following equation:
% increase ¼100

SUVpeakðESOAÞ SUVpeakðESOBÞ

SUVpeakðESO BÞ
(1)
Statistical Considerations
The analysis was carried out with SAS software (v9.3,
SAS Institute, Cary, NC). Descriptive statistics were used
to summarize the demographics and disease character-
istics. Fisher’s exact test and Wilcoxon Mann-Whitney
test were performed to test their association with the
development of any RE (grade >0) and speciﬁcally
grade 3. The Wilcoxon Mann-Whitney test was also usedto test association of PET and volumetric (primary and
nodal GTV) and dosimetric parameters, such as the
percentage increase in SUVpeak, V50, and V60, with
development of any grade of RE and grade 3 RE.
Furthermore, the C-statistic (area under the curve
[AUC]) was calculated for these parameters to demon-
strate their predictivity of development of any grade of
RE (grade >1) and particularly grade 3.Ethical Considerations
The study protocol was approved by the local
research ethics board and independent ethics committee.
It was conducted in accordance with the ethical princi-
ples from the Declaration of Helsinki and was consistent
with the guidelines of the International Conference on
Harmonization Good Clinical Practice and applicable
regulatory requirements.
Figure 2. Esophagus segmentation for evaluation.
Table 1. Patient Demographics and Characteristics
Variable Value (N ¼ 27)
Median age (range), y 63 years (36–79)
ECOG performance status, n (%)
0 15 (56%)
1 12 (44%)
Sex, n (%)
Female 7 (26%)
Male 20 (74%)
Histologic diagnosis, n (%)
NSCLC NOS 4 (14.8%)
Adenocarcinoma 18 (66.7%)
Squamous 5 (18.5%)
Tumor (T) stage, n (%)
T1 8 (29.6%)
T2 6 (22.2%)
T3 8 (29.6%)
T4 3 (11.1%)
Tx 2 (7.4%)
Nodal (N) stage, n (%)
N1 2 (7.4%)
N2 18 (66.7%)
N3 7 (25.9%)
Disease stage, n (%)
2A 2 (7.4%)
3A 14 (51.9%)
3B 11 (40.7%)
Gross tumor volume (cc)
Primary, median (range) 69.3 (0–351.4)
Nodal, median (range) 25.9 (4.6–152.0)
ECOG, Eastern Cooperative Oncology Group; NSCLC NOS, non–
small cell lung cancer not otherwise speciﬁed.
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A total of 27 patients on the study protocol were
treated with CRT. Their demographic characteristics are
shown in Table 1. All patients completed radiotherapy,
with 25 patients (93%) receiving 60 to 66 Gy and two
patients receiving 70 to 74 Gy in 2-Gy fractions. The two
patients receiving 70 to 74 Gy had T2N2 disease and
were considered to beneﬁt from a higher dose while
meeting the normal tissue constraints. Concurrent
chemotherapy regimens included carboplatin/cisplatin
(days 1, 8, 29, and 36) with etoposide (days 1–5 and 29–
33) for 19 patients, cisplatin with pemetrexed (days 1,
22, and 43) for four patients, and carboplatin with
paclitaxel (weekly) for four patients. Analysis of the
development of RE in relation to concurrent chemo-
therapy regimen was not possible because of the small
number of patients.
Of the 27 patients, 24 (89%) completed all concur-
rent chemotherapy cycles at the full dose. The remaining
three patients missed one cycle on account of pancyto-
penia, grade 3 RE, and intercurrent infection. Although
22 patients were due to receive adjuvant chemotherapy
3 to 4 weeks after CRT, only 16 patients completed
all planned cycles. As RE developed in all patients
during CRT, with only one patient peaking with
grade 3 RE during adjuvant chemotherapy, all patients
receiving adjuvant chemotherapy were included in the
analysis.
The maximum esophageal dose was 67.8 Gy (95%
conﬁdence interval: 63.2–72.4). RE developed in 20
patients (74%), and 14 of them reached maximum grade2 toxicity at a median time of 3 weeks (range 1–5
weeks). Six patients (22%) had grade 3 toxicity that
occurred at a median of 6 weeks (range 5–17.5 weeks).
No grade 4 or 5 toxicity was noted in the study group.
The time trend for development of RE during chemo-
radiation and timing of concurrent chemotherapy are
shown in Figure 3. Of the six patients with grade 3
toxicity, two peaked after completion of radiotherapy (at
week 10 and week 17.5); grade 3 toxicity developed
during adjuvant chemotherapy in only one of these
patients.
As shown in Table 2, there were no differences be-
tween patients with or without RE in terms of Eastern
Cooperative Oncology Group performance score, age, sex,
or histologic diagnosis. Stage of cancer was signiﬁcant
(p¼ 0.04) for development of esophagitis inasmuch as no
toxicity developed in either of the two patients with
stage II cancer. Tumor (T) and nodal (N) stage were not
signiﬁcantly associated with development of RE of any
grade or grade3.With regard toprimaryGTVor nodal GTV
volumes, we did not note any signiﬁcant differences be-
tween patients inwhomanyRE or grade 3 RE in particular
developed (as shown in Table 3).
Figure 3. Development of esophagitis during chemoradiation and timing of concurrent chemotherapy.
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to ESO-B in patients in whom RE developed compared
with that in patients with no RE was signiﬁcant at
week 4 (p ¼ 0.01) and week 7 (p ¼ 0.03), as is also
shown in Table 3. Those with grade 3 RE also had a
signiﬁcant percentage increase in SUVpeak (ESO-A) at
week 2 (p ¼ 0.01) and week 7 (p ¼ 0.03) compared
with those having lower than grade 3 toxicity (see
Table 3).
Tumor dose and maximum esophageal dose showed
no signiﬁcant difference in patients in whom any RE or
grade 3 toxicity developed. Patients with RE had a mean
V50 of 43.3% (± 11.4) and V60 of 30.9% (± 14.2). Both
these values were signiﬁcantly higher (p ¼ 0.04) than in
patients with no RE; however, neither V50 nor V60 was
signiﬁcant for predicting the development of grade 3
toxicity.
We calculated the C-statistic for V50 and V60 and the
percentage increase in SUVpeak at week 2 for predicting
grade 3 RE and found that the percentage increase in
SUVpeak (week 2) (AUC 0.69) was similar to V50 (AUC
0.67) and V60 (AUC 0.66) from the standpoint of being
predictive for the development of RE.Discussion
This study is the ﬁrst to look at evolving FDG-PET
changes at multiple time points during the course of
CRT in relation to the development of RE. The incidence
and timing of development of RE that we noted in our
study population were similar to those previously re-
ported in patients undergoing CRT.5,15,18,19 We did not
ﬁnd any correlation between age, histologic ﬁndings,
performance status, or sex and development of RE. We
noted a signiﬁcant difference in number of patients with
grade 3 RE compared with the number of patients with
grade 2, which has been noted in other studies7 and
would be in keeping with higher doses delivered close to
the esophagus because of mediastinal disease. We did
not ﬁnd any signiﬁcant differences between T stage and
N stage from the standpoint of relationship to develop-
ment of RE, and there were no signiﬁcant differences
based on the tumor or nodal GTV. This fact may be
explained by the location of the primary or nodal disease
in relation to the esophagus, particularly if they were
predominantly right sided.
Our data show an increase in SUVpeak during treat-
ment in patients in whom RE develops compared with in
Table 2. Patient Demographics and Correlation with Esophagitis of Any Grade and Grade 3
Variable
Esophagitis (Grade > 0) No Esophagitis
p Value
Grade <3 RE Grade 3 RE
p ValueN ¼ 20 N ¼ 7 N ¼ 21 N ¼ 6a
Median age (range) 64 (36–79) 54 (37–71) 0.32 63 (37–79) 65 (36–78) 0.58
ECOG performance status, n (%)
0 11 (55%) 4 (57%) 1.00 13 (62%) 2 (33.3%) 0.36
1 9 (45%) 3 (43%) 8 (38%) 4 (66.7%)
Sex, n (%)
Female 5 (25 %) 2 (29%) 1.00 5 (24%) 2 (33.3%) 0.63
Male 15 (75%) 5 (71%) 16 (76%) 4 (66.7%)
Histologic diagnosis, n (%)
NSCLC NOS 1 (5.0%) 3 (42.9%) 0.06 3 (14.3%) 1 (16.7%) 0.53
Adenocarcinoma 15 (75.0%) 3 (42.9%) 15 (71.4%) 3 (50.0%)
Squamous 4 (20.0%) 1 (14.3%) 3 (14.3%) 2 (33.3%)
Stage, n (%)
2A 0 (0.0%) 2 (28.6%) 0.04 2 (9.5%) 0 (0.0%) 0.48
3A 10 (50.0%) 4 (57.1%) 12 (57.1%) 2 (33.3%)
3B 10 (50.0%) 1 (14.3%) 7 (33.3%) 4 (66.7%)
Tumor (T) stage, n (%)
T1 7 (35.0%) 1 (14.3%) 0.56 7 (33.3%) 1 (16.7%) 0.91
T2 4 (20.0%) 2 (28.6%) 4 (19.0%) 2 (33.3%)
T3 5 (25.0%) 3 (42.9%) 6 (28.6%) 2 (33.3%)
T4 3 (15.0%) 0 (0.0%) 2 (9.5%) 1 (16.7%)
Tx 1 (5.0%) 1 (14.3%) 2 (9.5%) 0 (0.0%)
Nodal (N) stage, n (%)
N1 0 (0.0%) 2 (28.6%) 0.08 2 (9.5%) 0 (0.0%) 1.00
N2 14 (70.0%) 4 (57.1%) 14 (66.7%) 4 (66.7%)
N3 6 (30.0%) 1 (14.3%) 5 (23.8%) 2 (33.3%)
aTotal patients with grade 3 RE, median time of onset 6 weeks (range 5–17.5 wk).
RE, radiation esophagatis; ECOG, Eastern Cooperative Oncology Group; NSCLC NOS, non–small cell lung cancer not otherwise speciﬁed.
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cant FDG-PET changes after delivery of 45 Gy, and
similarly, other studies have also reported changes in
SUV uptake related to the development of RE at single
time points during or after radiotherapy.15 Compara-
tively, our study demonstrated a trend toward progres-
sively increasing SUVpeak from baseline during
treatment, with the increase reaching signiﬁcance by
week 4 and week 7 and correlating with delivery of
40 Gy versus between 66 and 70 Gy. Clinically, in most
patients the onset of RE was noted during week 2 and 3
of treatment, which may limit the application of these
reported PET changes in practice.
Our study is also the ﬁrst to report on FDG-PET
changes speciﬁc to grade 3 toxicity, as is also shown in
Table 3. The increase in SUVpeak for patients who had
grade 3 RE compared with in those with lower than
grade 3 RE was signiﬁcant at week 2 and again at week
7, whereas the peak in clinical presentation occurred at
week 6. These results suggest the existence of an early
signiﬁcant increase in SUVpeak at week 2 in patients in
whom grade 3 toxicity develops. Identifying patients at
risk for the development of RE ahead of clinical pre-
sentation could allow for earlier intervention to reducemorbidity. To date, however, there has been a lack of
data indicating whether earlier management of RE
would alter the clinical course of RE and morbidity.11
Previous studies using interventions such as sucral-
fate20 and amifostine21 have not shown signiﬁcance in
preventing or reducing the incidence of RE, and medical
management continues to be supportive. This may be
due to the fact that the previous studies were performed
on all patients and, unlike our study, did not have a
predictive tool to identify patients at higher risk for the
development of RE.
The trend toward increasing SUVs in patients with
any grade of RE was not seen in patients with grade 3
toxicity. In the case of patients with grade 3 RE, SUVs at
week 4 were not signiﬁcantly increased; however, they
did peak signiﬁcantly by week 7. A review of the indi-
vidual PET data from the six patients with grade 3
toxicity shows that in some patients, the FDG-PET SUV
decreased or had a smaller increase between week 2 and
4; however, it peaked in all of them by week 7. Clinically,
grade 2 toxicity had developed in all these patients by
week 2 and they were given supportive treatment in the
form of analgesia, anti-reﬂux medications, sucralfate,
anti-inﬂammatory solutions, or combinations thereof.
Table 3. Comparison of Volumetric, Dosimetric, and PET Parameters with Any Grade and Grade 3 Radiation Esophagitis
Variable
Esophagitis (Grade >0) No Esophagitis
p Value
Grade <3 RE Grade 3 RE
p ValueN ¼ 20 N ¼ 7 N ¼ 21 N ¼ 6a
Primary GTV (cc), mean ± SD 87.4 ± 93.4 62.8 ± 39.4 0.76 61.4 ± 60.8 149.7 ± 116.4 0.06
Primary GTV (cc), median (range) 69.4 (0.0–351.5) 69.2 (6.9–106.6) 65.6 (0.0–236.2) 143.8 (12.3–351.5)
Node GTV (cc), mean ± SD 40.1 ± 37.2 41.6 ± 39.3 0.98 37.4 ± 37.9 51.4 ± 34.6 0.23
Node GTV (cc), median (range) 25.2 (4.6–152.1) 27.2 (5.5–106.5) 23.8 (4.6–152.1) 43.2 (19.7–114.6)
Tumor dose (Gy), mean ± SD 64.8 ± 3.8 65.1 ± 2.3 0.76 64.5 ± 3.0 66.3 ± 4.5 0.38
Max. esophagus dose (Gy),
mean ± SD
68.8 ± 4.3 65.1 ± 4.8 0.11 67.0 ± 3.9 70.5 ± 6.3 0.37
Mean V50 ± SD (%) 43.3 ± 11.4 28.2 ± 18.3 0.04 38.2 ± 15.9 43.5 ± 9.6 0.54
Mean V60 ± SD (%) 30.9 ± 14.2 16.5 ± 15.3 0.04 26.0 ± 15.6 31.0 ± 16.2 0.62
Increase in SUVpeak, %
Week 0, mean ± SD 8.1 ± 18.6 1.9 ± 11.8 0.11 2.7 ± 15.1 15.2 ± 22.8 0.21
Week 2, mean ± SD 10.9 ± 14.6 5.8 ± 11.1 0.46 7.0 ± 14.4 18.5 ± 5.0 0.01
Week 4, mean ± SD 23.5 ± 39.5 3.7 ± 11.2 0.01 15.8 ± 39.6 18.7 ± 23.8 0.54
Week 7, mean ± SD 45.5 ± 43.5 8.0 ± 14.7 0.03 26.6 ± 35.2 68.0 ± 48.4 0.03
aTotal patients with grade 3 RE, median time of onset 6 weeks (range 5–17.5 weeks).
RE, radiation esophagatis; GTV, gross tumor volume; Max., maximum; SD, standard deviation; V50, volume of esophagus receiving 50 Gy;
V60, volume of esophagus receiving 60 Gy; SUVpeak, peak standard uptake value.
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in patients with grade 3 toxicity may be due to these
interventions for RE having the effect of leading to a
reduction in SUV uptake at week 4.
Comparatively, the patients with lower than grade 3
RE included asymptomatic patients and patients with
grade 2 disease, who had symptoms ranging from mild
and requiring no intervention to severe painful
dysphagia affecting intake. Use of supportive treatments
in this group was variable and irregular, which may
explain why the trend in SUVs did not ﬂuctuate. These
ﬁndings suggest that interventions to alleviate the
symptoms and severity of RE may be associated with a
decrease in FDG-PET uptake. PET changes correlating
with tumor response have been described, but no formal
studies correlating change in SUV with treatment of RE
have been performed.
Our data relate to RE due to CRT for lung cancer. It is
well documented that RE is a common toxicity resulting
from lung radiotherapy and that the severity increases
with use of concurrent chemotherapy.1,3 Studies exam-
ining PET changes resulting from RE have included
mainly patients undergoing CRT and have identiﬁed the
factors of radiotherapy dose and volume in relation to
RE. However PET changes are noted in benign esopha-
geal conditions, including gastric reﬂux and Candida
infection,22,23 and they have been described in patients
with reﬂux esophagitis secondary to chemotherapy.24 In
chemotherapy-induced reﬂux esophagitis, PET uptake
was noted to gradually increase during and following
completion of chemotherapy. In our study the region of
high SUV uptake was in the region of high dose and
tumor volume and therefore is felt to be related to thecombined effect of CRT, rather than chemotherapy
related reﬂux esophagitis or Candida infection. Although
patients received adjuvant chemotherapy, we thought it
less likely to be contributing to RE because the onset of
the toxicity occurred during CRT and in all patients
except one, it peaked before commencement of adjuvant
chemotherapy.
The application of dosimetric parameters in our
study group showed that both V50 and V60 did correlate
with development of RE, as was suggested by previous
studies.3,6 However, neither V50 nor V60 was signiﬁ-
cantly different in patients with grade 3 versus less than
grade 3 toxicity—a ﬁnding that differs from those of the
meta-analysis by Palma et al. The C-statistic suggests
that using the percentage increase in SUVpeak at week 2
may be as predictive of grade 3 RE as are V50 and V60;
however, our study has the limitations of small numbers
of patients and grade 3 toxicity events.
In this study, we excluded a region of esophagus
within the planning target volume to reduce the con-
founding FDG-PET changes related to tumor response.
This approach may have excluded the region of esoph-
agus receiving the highest dose, thus resulting in an
underestimation of our values for SUVpeak. Even with this
potential underestimation, however, we still demon-
strated signiﬁcant changes in SUV with respect to
development of RE.
Our patient population was small but less heteroge-
neous that those of other studies examining RE and FDG-
PET uptake. We included patients who were known to be
at higher risk for the development of RE (predominantly
grade 3 disease) and all of whom were receiving CRT in a
dose of 2 Gy per fraction. The data collected are unique
220 Mehmood et al Journal of Thoracic Oncology Vol. 11 No. 2in providing progressive FDG-PET changes related to
development of RE in a population that may beneﬁt from
adaptive planning to improve outcomes. On the basis of
our group’s previous work on adaptive planning using
FDG-PET, it was noted that dose escalation is feasible in
more patients earlier in the course of radiotherapy (in
week 0 or 2) rather than later (in week 4).25 This study
supports consideration of performing FDG-PET in week
2 to gain additional information regarding esophageal
toxicity, which could inﬂuence decisions related to dose
escalation. On the basis of the ﬁndings of both studies,
we are currently undertaking a prospective study using
PET in week 0 for dose escalation, and our protocol in-
cludes the option of performing a PET scan in week 2 to
explore prevention of RE.Conclusions
Our study highlights the complexity of using FDG-PET
to evaluate RE and predict its course. In moving toward
adaptive planning and dose escalation to improve out-
comes, our ﬁndings suggest that evaluating patients with
4D PET at week 2 of CRT could be advantageous in
highlighting those at risk for the development of grade 3
RE, a signiﬁcant toxicity. Such evaluation may also pro-
vide an opportunity to consider earlier aggressive
intervention in at-risk patients and investigate whether
such intervention would alter the course of toxicity.
Further prospective research on using FDG-PET as a tool
for improving the therapeutic ratio of CRT in locally
advanced NSCLC is warranted.
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